Hepion Pharma's NASH drug is set for Phase 2b after clearing the safety bar
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic drugs for the liver disease treatment arising from non-alcoholic steatohepatitis (NASH), declaring positive topline results from its Phase 2a ‘AMBITION’ NASH clinical trial. All primary endpoints of the trial were fulfilled.
AMBITION was a Phase 2a randomized, multi-center, placebo-controlled, a single-blind trial designed to evaluate once-daily oral administration of CRV431 at doses of 75 mg and 225 mg administered as soft gelatin capsules to expected F2 and F3 NASH subject...
